Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

GILD

Gilead Sciences, Inc

Nov 04 • 04:00PM ET

89.84

Dollar change +0.33
Percentage change 0.37	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB MOAT VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	109.80	EPS (ttm)	0.82	Insider Own	0.21%	Shs Outstand	1.25B	Perf Week	1.22%
Market Cap	112.72B	Forward P/E	12.36	EPS next Y	7.27	Insider Trans	-2.57%	Shs Float	1.24B	Perf Month	6.21%
Income	1.05B	PEG	17.46	EPS next Q	1.51	Inst Own	84.89%	Short Float	1.33%	Perf Quarter	21.09%
Sales	27.78B	P/S	4.06	EPS this Y	-43.49%	Inst Trans	-0.02%	Short Ratio	2.69	Perf Half Y	37.08%
Book/sh	14.67	P/B	6.12	EPS next Y	91.33%	ROA	1.82%	Short Interest	16.48M	Perf Year	10.60%
Cash/sh	3.35	P/C	26.85	EPS next 5Y	6.29%	ROE	5.34%	52W Range	62.07 - 89.74	Perf YTD	10.90%
Dividend Est.	3.08 (3.42%)	P/FCF	16.35	EPS past 5Y	1.55%	ROI	2.64%	52W High	0.11%	Beta	0.19
Dividend TTM	3.06 (3.41%)	Quick Ratio	0.95	Sales past 5Y	4.16%	Gross Margin	77.60%	52W Low	44.74%	ATR (14)	1.42
Dividend Ex-Date	Sep 13, 2024	Current Ratio	1.14	EPS Y/Y TTM	-80.78%	Oper. Margin	36.44%	RSI (14)	69.87	Volatility	1.46% 1.55%
Employees	18000	Debt/Eq	1.28	Sales Y/Y TTM	2.05%	Profit Margin	3.79%	Recom	1.97	Target Price	88.58
Option/Short	Yes / Yes	LT Debt/Eq	1.18	EPS Q/Q	55.31%	Payout	66.62%	Rel Volume	1.00	Prev Close	89.51
Sales Surprise	3.75%	EPS Surprise	25.05%	Sales Q/Q	5.46%	Earnings	Nov 06 AMC	Avg Volume	6.12M	Price	89.84
SMA20	2.94%	SMA50	6.94%	SMA200	21.09%	Trades		Volume	6,123,046	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75

Show Previous Ratings

Nov-03-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
Nov-01-24 09:15AM	Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Oct-31-24 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:00AM	AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies (ACCESSWIRE)
10:01AM	Loading…
Oct-30-24 10:01AM	Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline (Zacks)
Oct-29-24 06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why (Zacks)
Oct-24-24 08:15AM	3 Absurdly Cheap Stocks That Pay High Dividends (Motley Fool)
Oct-23-24 06:00PM	Why Gilead Sciences (GILD) Dipped More Than Broader Market Today (Zacks)
Oct-22-24 12:36PM	Gilead and MSD to advance once-weekly HIV treatment to Phase III (Clinical Trials Arena)
09:00AM	Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 (Business Wire)
Oct-21-24 12:28PM	Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks (Benzinga)
Oct-19-24 05:09PM	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 (Business Wire)
11:57AM	Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE (Insider Monkey)
Oct-18-24 02:34PM	After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment (Benzinga)
08:50AM	Loading…
08:50AM	Gilead withdraws bladder cancer drug in US after failed trial (Reuters)
Oct-17-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Oct-15-24 06:00PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Oct-14-24 10:01AM	How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket (Benzinga)
Oct-10-24 07:22PM	Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? (Insider Monkey)
Oct-09-24 05:52PM	Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ... (GuruFocus.com)
04:05PM	Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024 (Business Wire)
08:30AM	Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 (Business Wire)
Oct-08-24 06:00PM	Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
09:25AM	Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic (ACCESSWIRE)
Oct-07-24 11:00AM	Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference (Business Wire)
02:52AM	AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history (Pharmaceutical Technology)
Oct-03-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
04:52AM	Gilead signs agreements to facilitate access to HIV prevention drug (Pharmaceutical Technology)
Oct-02-24 10:43AM	Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries (PR Newswire)
08:30AM	Loading…
08:30AM	Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries (Business Wire)
Oct-01-24 06:00PM	Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Sep-25-24 09:55AM	Championing HIV Services for LGBTQ+ Youth (ACCESSWIRE)
Sep-24-24 06:00PM	Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Sep-23-24 04:06PM	AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug (Investor's Business Daily)
02:12PM	Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles (Benzinga)
09:38AM	AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug (Investor's Business Daily)
Sep-21-24 12:00PM	Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income (Benzinga)
07:36AM	3 Dirt Cheap Stocks to Buy Right Now (Motley Fool)
Sep-19-24 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Sep-18-24 01:30PM	Working to Build Next-Generation Cancer Therapies (ACCESSWIRE)
Sep-17-24 06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why (Zacks)
Sep-16-24 06:00AM	This 'forgotten child' is one of the best biotech plays: Analyst (Yahoo Finance Video)
01:52AM	Gileads lenacapavir: HIV prospects strongest in long-acting combos with Mercks islatravir (Clinical Trials Arena)
Sep-14-24 08:45AM	Got $200? 2 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
01:51AM	Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
Sep-13-24 06:55AM	Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial (BioPharma Dive)
Sep-12-24 06:11PM	Why Gilead Sciences Stock Thrashed the Market Today (Motley Fool)
04:05PM	Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention (Investor's Business Daily)
01:46PM	Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections (Benzinga)
10:20AM	Gilead Unveils More Positive Data on HIV Prevention Shot (Barrons.com)
10:07AM	Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug (The Wall Street Journal)
09:45AM	Gilead says HIV prevention injection reduced cases by 96%, sending shares higher (Investing.com)
09:35AM	Helping End HIV - Gilead Sciences (ACCESSWIRE)
08:30AM	Gileads Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada in Second Pivotal Phase 3 Trial (Business Wire)
Sep-11-24 05:50PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
03:52AM	Gilead and Genesis partner to create novel therapies using AI (Pharmaceutical Technology)
Sep-10-24 09:20AM	Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company (ACCESSWIRE)
08:00AM	Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies (Business Wire)
Sep-08-24 01:57AM	Gilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock? (Insider Monkey)
Sep-06-24 09:15AM	Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey (ACCESSWIRE)
Sep-05-24 08:00AM	Gilead to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer (Business Wire)
Sep-04-24 09:25AM	Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers (ACCESSWIRE)
06:52AM	Avenzo and Gilead partner for breast cancer combination regimen trial (Clinical Trials Arena)
Aug-30-24 05:34PM	Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. (Barrons.com)
02:05PM	How Gilead Sciences, Virtus Investment And Hess Midstream Could Put Cash In Your Pocket (Benzinga)
01:46AM	Insider Sale: Johanna Mercier Sells 9,513 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia)
Aug-27-24 09:15AM	'The Adventure Jar,' Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together (ACCESSWIRE)
Aug-26-24 01:19PM	Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock? (Zacks)
Aug-22-24 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
Aug-21-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
Aug-20-24 02:00PM	How To Earn $100 Per Month From Gilead Sciences Stock (Benzinga)
09:00AM	Gilead Sciences: 'One of Best Employers for Women' by Forbes (ACCESSWIRE)
08:30AM	Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences (ACCESSWIRE)
Aug-19-24 05:12AM	Gilead partners with PANTHERx for LIVDELZI distribution (Pharmaceutical Technology)
Aug-17-24 01:44AM	Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi (Zacks)
Aug-15-24 01:13PM	Gileads PBC therapy Livdelzi bags accelerated approval (Pharmaceutical Technology)
09:09AM	FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal (Benzinga)
06:53AM	FDA clears Gilead drug acquired in $4.3B buyout (BioPharma Dive)
Aug-14-24 05:01PM	Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
01:59PM	Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA (Business Wire)
Aug-13-24 08:45AM	Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia (ACCESSWIRE)
Aug-10-24 06:50AM	3 Stocks Retirees Should Absolutely Love (Motley Fool)
Aug-09-24 04:34PM	These Stocks Moved the Most Today: Expedia, Akamai, Lilly, E.l.f. Beauty, Doximity, Rocket Lab, Five9, Array, and More (Barrons.com)
04:11PM	Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat (Investor's Business Daily)
02:43PM	These Stocks Are Moving the Most Today: Expedia, Akamai, Lilly, E.l.f. Beauty, Doximity, Rocket Lab, Five9, Array, and More (Barrons.com)
12:22PM	Q2 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
11:15AM	These Stocks Are Moving the Most Today (Barrons.com)
09:45AM	Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised (Zacks)
08:23AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
06:52AM	Gilead Sciences reports net income rise in Q2 2024 (Pharmaceutical Technology)
01:12AM	Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 09:45PM	Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:16PM	Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations (Investor's Business Daily)
05:15PM	Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:20PM	Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat (Investor's Business Daily)
04:12PM	Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment (Barrons.com)
04:11PM	Gilead: Q2 Earnings Snapshot (Associated Press Finance)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience